Content Detail

• Content META

  Title	Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
  ID	31508949
  External ID	2e7552c7-bf0a-308a-9a8b-aa01e5922093
  Author
  Published Date	June 16, 2026, 11:06 a.m.
  Summary	Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves Agenus logo MarketBeat Tue, June 16, 2026 at 9:06 AM PDT 7 min read AGEN Key Points Interested in Agenus Inc.? Here are
  Tags
  URL	https://www.marketbeat.com/instant-alerts/agenus-annual-meeting-botbal-leads-cancer-drug-push-as-balance-sheet-improves-2026-06-16/?utm_source=yahoofinance&utm_medium=yahoofinance
  Sentiment	Negative: 0.01524    Neutral: 0.93268    Positive: 0.05208
  Relevance	0.02128

• Content Details

  Content ID	38359545
  Key	bd0a1880-7828-4bc3-8988-d3fa9e63186e
  Content	Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves Agenus logo MarketBeat Tue, June 16, 2026 at 9:06 AM PDT 7 min read AGEN Key Points Interested in Agenus Inc.? Here are five stocks we like better. BOT/BAL remains Agenus’ main focus as the company advances botensilimab/balstilimab in hard-to-treat cancers, especially refractory MSS metastatic colorectal cancer. Management said the program has treated about 1,300 patients and is now the lead candidate for phase 3 and regulatory development. The global phase 3 BATMAN trial is underway, comparing BOT/BAL with best supportive care in refractory MSS or pMMR metastatic colorectal cancer. Agenus expects the first overall survival readout in the second half of 2028 . Agenus said its balance sheet has improved after the Zydus collaboration, rising from about $3 million in cash at the end of 2025 to roughly $35 million in cash at the end of Q1 2026, plus additional ATM proceeds afterward. The company is also preparing potential accelerated approval filings in the U.S. and conditional marketing authorization plans in Europe. Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while working to strengthen its financial position and pursue regulatory pathways in the United States and Europe. Chairman and Chief Executive Officer Garo Armen said the past year had been “one of the most important periods” in the company’s history, but also “one of the most difficult.” He said Agenus had made “hard decisions” to sharpen its focus around BOT/BAL, which the company is developing in cancers that have historically resisted immunotherapy, including microsatellite stable, or MSS, colorectal cancer. → Viasat's Orbiting Profits: Space Force Jackpot? Armen said the company’s key objectives include building clinical evidence for BOT/BAL, supporting responsible patient access where permitted, moving the program into randomized phase 3 development, advancing regulatory plans in the U.S. and Europe, and strengthening the company’s balance sheet and operating foundation. BOT/BAL Remains Lead Development Focus Armen described BOT/BAL as a combination of an Fc-engineered CTLA-4 antibody and a PD-1 antibody, saying Agenus does not view the regimen as “simply another CTLA-4 and PD-1 doublet.” He said botensilimab was designed to help activate a broader immune response, including by priming T cells, reducing suppressive regulatory T cells, engaging myeloid cells and supporting immune memory. → What to Expect From Q2 Earnings as Tech Strength Broadens Across phase 1 and phase 2 trials, Armen said approximately 1,300 patients have been treated with botensilimab and balstilimab, with clinical activity observed in more than nine metastatic late-line cancer settings. The company’s most mature data remain in refractory MSS metastatic colorectal cancer, which Armen said continues to be Agenus’ lead regulatory development focus. Story Continues In heavily pretreated MSS metastatic colorectal cancer patients without active liver metastases, Armen said BOT/BAL has demonstrated 42% two-year overall survival and median overall survival of about 21 months. He said the company has also observed activity across multiple difficult-to-treat tumors, including colorectal cancer, ovarian cancer, sarcoma, lung cancer, hepatocellular cancer and refractory or resistant melanoma. → Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Agenus Chief Medical Officer Dr. Steven O’Day said melanoma data presented at ASCO included 36 refractory metastatic patients, with a confirmed RECIST overall response rate of 22%. In a subgroup that had failed CTLA-4 and PD-1 therapy, he said the response rate was 29%, with survival plateaus between 40% and 60% after the data were allowed to mature for at least two and a half years. Phase 3 BATMAN Trial Underway Armen said the global phase 3 BATMAN trial began enrolling patients in April. The study is evaluating BOT/BAL against best supportive care in patients with refractory, unresectable MSS or pMMR metastatic colorectal cancer. O’Day said the trial currently has 21 active sites in Canada and is expected to reach 30 sites “very shortly.” He said Australia and New Zealand are expected to open with a first patient in within the next month, with France to follow over the summer. Because the trial is driven by overall survival events, O’Day said the company expects the first reporting of the survival analysis “probably in the second half of 2028.” Regulatory Plans and Access Programs Armen said Agenus is preparing for regulatory engagement in the U.S. and Europe, including potential accelerated approval and conditional marketing authorization pathways. He said the company is assembling a regulatory package based on more mature data and a safety data set covering roughly 1,300 or more patients. Asked what Agenus is waiting for before filing with the FDA or European regulators, Armen said the company had previously received FDA guidance not to pursue accelerated approval when the data were less mature. He said the data are now “more mature” and “compelling,” but added that preparing an accelerated approval application requires substantial work and validation. “It will not take years,” Armen said. “We hope that it will take a reasonable few quarters for us to be able to submit the data for accelerated approval.” Armen also discussed patient access programs outside the U.S. He said BOT/BAL is available in France through the national Autorisation d’accès compassionnel framework for eligible French patients with MSS metastatic colorectal cancer without active liver metastases. He said platinum-resistant or platinum-refractory ovarian cancer and certain advanced soft tissue sarcomas are also allowed under the French AAC program. Outside France, Armen said BOT/BAL may be available in select countries through paid named-patient programs where permitted by local regulation, including in parts of Europe and South America. He said the programs are physician-driven and not promotional. Agenus recognized $3.2 million in initial income associated with BOT/BAL supplied through authorized access pathways in the fourth quarter of 2025 and $4.6 million in pre-commercial product revenue in the first quarter of 2026, Armen said. Balance Sheet and Collaboration Updates Armen said Agenus ended 2025 with approximately $3 million in cash and cash equivalents, calling it “a very difficult position.” He said the company’s January strategic collaboration with Zydus Lifesciences provided upfront capital, strengthened the balance sheet and secured dedicated U.S. biologics manufacturing capacity for clinical development, access programs and potential future commercial supply. After the Zydus transaction and payments of several obligations, Agenus ended the first quarter of 2026 with approximately $35 million in cash and cash equivalents, Armen said. Subsequent to the quarter, the company received about $11.7 million in net proceeds from sales of common stock under its at-the-market program. Armen said Agenus is targeting approximately $50 million in annualized ongoing operating expenses to support BOT/BAL. He said the company is evaluating financing and partnering opportunities as appropriate. During the Q&A, Armen said interest in immuno-oncology partnerships had been weak for the past two years, but that Agenus received inbound inquiries at ASCO from companies, including regional companies. He said the company is renewing efforts to engage potential collaborators, with an emphasis on regional collaboration. Shareholders Approve Annual Meeting Proposals During the formal portion of the meeting, Chief Communications and Government Relations Officer Stefanie Nacar said holders representing at least 51% of outstanding shares were present in person or by proxy, establishing a quorum. Nacar said shareholders approved all proposals presented at the meeting, including the election of Garo Armen and Jennifer Buell as Class 2 directors, equity plan-related amendments, a one-time stock option exchange program, an advisory vote on named executive officer compensation for 2025, and the ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Agenus said it expects to report preliminary or final voting results in a Form 8-K filing with the SEC within four business days after the meeting. About Agenus (NASDAQ:AGEN) Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies. Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com. The article " Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves " was originally published by MarketBeat. View MarketBeat's top stocks for June 2026 . View Comments Terms and Privacy Policy Your privacy controls WA Consumer Health Privacy Policy More Info
  Content Reference URL	None

• Publisher

  Publisher Name	r/StockMarket (#9510)
  Publisher URL	marketbeat.com
  Description	None
  Trust Flow Score	28
  Citation Flow Score	71

• Data Source

  Data Source Name	Yahoo Finance News (#2)
  Data Source Type	news
  Data Source URL	https://finance.yahoo.com/
  Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
  Weight	10